Antisense Oligonucleotides Targeting CTGF mRNA
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for disorders associated with dysregulated human connective tissue growth factor (CTGF) expression are inadequate, as existing methods lack specificity and efficacy in modulating CTGF levels, which are implicated in various fibrotic and proliferative diseases.
Innovation Solution
Development of synthetic antisense oligonucleotides complementary to specific regions of human CTGF mRNA, which can inhibit or decrease CTGF mRNA and protein expression, thereby addressing the underlying cause of associated diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatment methods are used for CTGF-associated disorders, then treatment is provided, but specificity and efficacy in modulating CTGF levels are insufficient
Solution Approach 1:
The patent modifies the molecular parameters of the treatment by using antisense oligonucleotides with specific nucleotide sequences complementary to CTGF mRNA. These oligonucleotides are designed with specific lengths (8-50 nucleotides) and chemical modifications (phosphorothioate backbones, 2'-fluoro or 2'-deoxyribose sugars) to achieve precise binding and modulation of CTGF expression, thereby improving specificity and efficacy compared to conventional treatments.
Solution Approach 2:
The patent replaces non-specific conventional treatment mechanisms with a molecular-level antisense mechanism. The antisense oligonucleotides bind directly to CTGF mRNA through complementary base pairing, preventing translation and reducing protein production. This molecular substitution provides targeted efficacy at the gene expression level, overcoming the limitations of conventional non-specific treatments.
2Reliability
If antisense oligonucleotides are designed with higher complementarity to CTGF mRNA, then modulation efficacy is improved, but oligonucleotide stability and cellular uptake may be compromised
Solution Approach 1:
The patent employs composite chemical structures by combining phosphorothioate linkages with modified sugar moieties (2'-fluoro or 2'-deoxyribose) in the antisense oligonucleotide design. This composite approach provides both high complementarity to CTGF mRNA for efficacy and enhanced structural stability against degradation, resolving the contradiction between binding strength and molecular stability.
Solution Approach 2:
The patent optimizes the physical-chemical parameters of the oligonucleotide by controlling nucleotide sequence composition, length (8-50 nucleotides), and chemical modifications. These parameter adjustments balance the competing requirements: sufficient complementarity for effective CTGF modulation while maintaining structural stability and appropriate cellular uptake characteristics.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antisense oligonucleotides effectively reduce CTGF mRNA and protein levels, providing a targeted therapeutic approach to treat CTGF-associated disorders by modulating gene expression and alleviating symptoms or preventing disease progression.
Implementation Method 1
synthetic antisense oligonucleotides that are complementary to nucleic acids encoding human CTGF and modulate CTGF mRNA expression
Data Source
AI summary
The present invention relates to antisense oligonucleotides that target human CTGF mRNA and inhibit CTGF mRNA expression. Additionally, regions of human CTGF mRNA that are exceptionally sensitive to antisense inhibition are disclosed. Pharmaceutical compositions comprising the antisense oligonucleotides are further disclosed. These compositions are useful for treating disorders and conditions that are associated with or influenced by CTGF expression.